Table 2 Distribution of S. pneumoniae isolates with intermediate/full resistance towards four antimicrobials by vaccine coverage. All isolates were sensitive to Levofloxacin
| Â | Number of isolates tested for susceptibility | Number of non-susceptible isolates (% of all isolates) | Number of non-typable tested for susceptibility | Number of non-susceptible PCV-13 serotypes | Number of non-susceptible non-PCV13 serotypes |
|---|---|---|---|---|---|
All isolates | 220 | 191 (86.8%) | 10 (4.5%) | 76 (34.5%) | 144 (65.5%) |
PEN (MIC 0.06–2) | 220a | 49 (22.3%) | 7 (3.2%) | 27 (12.3) | 13 (6.0%) |
PEN (MIC > 2) | 1 (0.5%) | 0 | 0 | 1 (0.5%) | |
TET (25 > I > =22) | 219b | 2 (0.9%) | 0 | 1 (0.5%) | 1 (0.5%) |
TET (R < 22) | 138 (63.0%) | 7 (3.2%) | 64 (29.2%) | 51 (2.3%) | |
SXT (18 ≥ I ≥ 15) | 220c | 32 (14.5%) | 1 (0.5%) | 10 (4.5%) | 18 (8.2%) |
SXT (R < 15) | 135 (61.4%) | 8 (3.6%) | 58 (26.4%) | 43 (19.5%) | |
ERY (S ≥ 22 > I ≥ 19) | 220d | 11 (5.0%) | 1 (0.5% | 4 (1.8%) | 5 ((2.3%) |
ERY (R < 19) | 24 (10.9%) | 0 | 15 (6.8%) | 8 (3.6%) | |
MDR ≥ 3 | 220 | 45 (20.5%) | 4 (1.8%) | 27 (12.3) | 18 (8.2%) |